The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of a study vaccine for pneumococcal diseases. This study will look at the effects of the study vaccine when given to healthy adults.
Pneumococcal diseases are illnesses caused by certain pneumoniae bacteria. These bacteria cause infections such as pneumonia, meningitis, and more. You can learn more about pneumococcal disease by watching this video.
Pneumococcal vaccines available today have been proven safe and effective, dramatically reducing rates of serious pneumococcal disease. However, while they defend against many strains of pneumococcal bacteria, they don’t protect against all.
Learn how you can help as a clinical trial participant or see if you may qualify.
Who may participate
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall stable health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to receive the study vaccine
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-49 years
Sex
All sexes
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study and choose to participate, screening and dosing may happen on the same day.
After screening, you will receive a single dose of either the study vaccine or an approved vaccine - used as a comparison - as an injection in the muscle of your upper arm. You will remain at the PCRU for a short time after dosing, but will be able to return home the same day. You will then have 2 follow-up visits about 1 and 3 months later, and a phone call about 6 months after vaccination.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of immune markers in your blood. You will be asked to complete an electronic diary to log things like how you feel and your temperature for a few days after receiving the study vaccine.
*You will be given the option to complete a nasal wash procedure during 2 of the visits. If you consent and complete both, you will receive an additional $200.
Take a look inside our specialized vaccine space and learn more about vaccine studies at the PCRU: View PCRU Vaccine Clinic
Required site visits
3 visits, 1 phone call
How long are the visits?
About 2-3 hours
How long is this study?
About 6 months
Compensation
Up to $3,350* upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
Watch a short video to learn more about pneumococcal disease
Get started — See if you may be eligible
Complete this 3-minute questionnaire about your health and medical history to see if this study might be a good fit for you. You may also call 1-800-254-6398 and speak with a PCRU representative to complete the prescreening or learn more about the study.
If you choose to submit your responses, a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you within 2-3 days to complete the process and discuss next steps.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. If you are not eligible or choose not to submit your responses, your individual data will not be linked to you directly but may be shared in anonymous reports of aggregate data. This prescreener is not a full assessment of eligibility. Only the study staff can determine if you are eligible to enroll in the study.
